Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 13/20 | 0.43 |
| ▸ | FPR2 | P25090 | 10/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1368575 | 1.00 | SCN9A (0.43) | SCN9AFPR2NTRK1PRCPHTT | |
| SCHEMBL1367405 | 0.80 | SCN9A (0.43) | SCN9AFPR2NTRK1PRCPHTT | |
| SCHEMBL27831875 | 0.79 | NTRK1 (0.41) | SCN9ANTRK1PRCPHTTPSEN1 | |
| SCHEMBL1367715 | 0.79 | JAK2 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15385254 | 0.79 | JAK2 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1368868 | 0.78 | PTGER4 (0.43) | SCN9AFPR2NTRK1 | |
| SCHEMBL1367919 | 0.78 | NTRK1 (0.40) | NTRK1PRCPHTTGPR55 | |
| SCHEMBL1368867 | 0.78 | PTGER4 (0.43) | SCN9AFPR2NTRK1 | |
| SCHEMBL1367922 | 0.78 | NTRK1 (0.40) | NTRK1PRCPHTTGPR55 | |
| SCHEMBL1368721 | 0.77 | SCN9A (0.38) | SCN9AFPR2NTRK1PRCPPSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673891-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2394999-B1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2014-01-29 | — | — | EP | disclosed |
| US-8586591-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20130131082-A1 | Aminopyrazine Derivative and Medicine | NIPPON SHINYAKU CO., LTD (JP) | 2013-05-23 | — | — | US | disclosed |
| EP-2394999-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131082-A1 | Aminopyrazine Derivative and Medicine | MC2R, AGTR2, AGTR1 | SCN9A 2756/4885FPR2 229/4885NTRK1 1477/4885 |
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | MC2R, CNR1, NPY2R | SCN9A 2833/4885FPR2 211/4885NTRK1 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.